Among all available biomedical agents, it has been suggested that RANKL inhibitor (Denosumab) has the most favorable potential for their application in orthodontic retention and prevention of external apical root resorption. It However, little is known about its effectiveness and the optimal usage protocol in orthodontics. Therefore, the overall goal of this presentation is to investigate the effect of local administration of two antiresorptive agents, Anti-RANKL Monoclonal Antibody (mAb) and Bisphosphonate (Clodronate) on OTM and alveolar bone remodeling in a rat model.
Learning Objectives:
After this lecture, attendees will be able to:
Show that reduction in tooth movement rate are different between Bisphosphonate and anti-RANKL mAb.
Demonstrate that bone biomarkers are affected with the application of Anti-RANKL mAb.
Show that there was no significant difference in microCT measures of alveolar bone (BV/TV and BMD) between study groups.
